Theraclion Reports Commercial Progress in H1 2026
Theraclion, a company specializing in non-invasive varicose vein therapy using High-Intensity Focused Ultrasound, has reported significant commercial momentum throughout the first half of 2026, reflecting progress across the sales cycle.
MALAKOFF, France–(BUSINESS WIRE)–Regulatory News: THERACLION (ISIN: FR0010120402; Ticker: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive varicose vein therapy using High-Intensity Focused Ultrasound (HIFU), today reports on its progress during the first half of 2026. By the end of the first half of 2026, Theraclion’s commercial acceleration is beginning to show clearly across every stage of the sales cycle. This momentum has been accompanied by signifi